Why FDA approval for vepdegestrant is a major shift in cancer therapy
On May 1, the U.S. Food and Drug Administration (FDA) approved the drug vepdegestrant for patients with ESR1-mutated, ER-positive, and HER2-negative advanced breast cancer. It is the world’s first therapy…